#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=Dysconnectivity of the medio-dorsal thalamic nucleus in drug-naïve first episode schizophrenia: diagnosis-specific or trans-diagnostic effect?
1-1	0-15	Dysconnectivity	_
1-2	16-18	of	_
1-3	19-22	the	_
1-4	23-35	medio-dorsal	_
1-5	36-44	thalamic	_
1-6	45-52	nucleus	_
1-7	53-55	in	_
1-8	56-66	drug-naïve	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
1-9	67-72	first	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
1-10	73-80	episode	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
1-11	81-94	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
1-12	95-96	:	_
1-13	97-115	diagnosis-specific	_
1-14	116-118	or	_
1-15	119-135	trans-diagnostic	_
1-16	136-142	effect	_
1-17	143-144	?	_

Text=Converging lines of evidence implicate the thalamocortical network in schizophrenia.
2-1	145-155	Converging	_
2-2	156-161	lines	_
2-3	162-164	of	_
2-4	165-173	evidence	_
2-5	174-183	implicate	_
2-6	184-187	the	_
2-7	188-203	thalamocortical	_
2-8	204-211	network	_
2-9	212-214	in	_
2-10	215-228	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-11	229-230	.	_

Text=In particular, the onset of the illness is associated with aberrant functional integration between the medio-dorsal thalamic nucleus (MDN) and widespread prefrontal, temporal and parietal cortical regions.
3-1	231-233	In	_
3-2	234-244	particular	_
3-3	245-246	,	_
3-4	247-250	the	_
3-5	251-256	onset	_
3-6	257-259	of	_
3-7	260-263	the	_
3-8	264-271	illness	_
3-9	272-274	is	_
3-10	275-285	associated	_
3-11	286-290	with	_
3-12	291-299	aberrant	_
3-13	300-310	functional	_
3-14	311-322	integration	_
3-15	323-330	between	_
3-16	331-334	the	_
3-17	335-347	medio-dorsal	_
3-18	348-356	thalamic	_
3-19	357-364	nucleus	_
3-20	365-366	(	_
3-21	367-370	MDN	_
3-22	371-372	)	_
3-23	373-376	and	_
3-24	377-387	widespread	_
3-25	388-398	prefrontal	_
3-26	399-400	,	_
3-27	401-409	temporal	_
3-28	410-413	and	_
3-29	414-422	parietal	_
3-30	423-431	cortical	_
3-31	432-439	regions	_
3-32	440-441	.	_

Text=Because the thalamus is also implicated in other psychiatric illnesses including post-traumatic stress disorder (PTSD) and major depressive disorder (MDD), the diagnostic specificity of these alterations is unclear.
4-1	442-449	Because	_
4-2	450-453	the	_
4-3	454-462	thalamus	_
4-4	463-465	is	_
4-5	466-470	also	_
4-6	471-481	implicated	_
4-7	482-484	in	_
4-8	485-490	other	_
4-9	491-502	psychiatric	_
4-10	503-512	illnesses	_
4-11	513-522	including	_
4-12	523-537	post-traumatic	_
4-13	538-544	stress	_
4-14	545-553	disorder	_
4-15	554-555	(	_
4-16	556-560	PTSD	_
4-17	561-562	)	_
4-18	563-566	and	_
4-19	567-572	major	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
4-20	573-583	depressive	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
4-21	584-592	disorder	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
4-22	593-594	(	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
4-23	595-598	MDD	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
4-24	599-600	)	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
4-25	601-602	,	_
4-26	603-606	the	_
4-27	607-617	diagnostic	_
4-28	618-629	specificity	_
4-29	630-632	of	_
4-30	633-638	these	_
4-31	639-650	alterations	_
4-32	651-653	is	_
4-33	654-661	unclear	_
4-34	662-663	.	_

Text=Here, we determined whether aberrant functional integration between the MDN and the cortex is a specific feature of schizophrenia or a trans-diagnostic feature of psychiatric illness.
5-1	664-668	Here	_
5-2	669-670	,	_
5-3	671-673	we	_
5-4	674-684	determined	_
5-5	685-692	whether	_
5-6	693-701	aberrant	_
5-7	702-712	functional	_
5-8	713-724	integration	_
5-9	725-732	between	_
5-10	733-736	the	_
5-11	737-740	MDN	_
5-12	741-744	and	_
5-13	745-748	the	_
5-14	749-755	cortex	_
5-15	756-758	is	_
5-16	759-760	a	_
5-17	761-769	specific	_
5-18	770-777	feature	_
5-19	778-780	of	_
5-20	781-794	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-21	795-797	or	_
5-22	798-799	a	_
5-23	800-816	trans-diagnostic	_
5-24	817-824	feature	_
5-25	825-827	of	_
5-26	828-839	psychiatric	_
5-27	840-847	illness	_
5-28	848-849	.	_

Text=Effective connectivity (EC) between the MDN and rest of the cortex was measured by applying psychophysiological interaction analysis to resting-state functional magnetic resonance imaging data of 50 patients with first episode schizophrenia (FES), 50 patients with MDD, 50 patients with PTSD and 122 healthy controls.
6-1	850-859	Effective	_
6-2	860-872	connectivity	_
6-3	873-874	(	_
6-4	875-877	EC	_
6-5	878-879	)	_
6-6	880-887	between	_
6-7	888-891	the	_
6-8	892-895	MDN	_
6-9	896-899	and	_
6-10	900-904	rest	_
6-11	905-907	of	_
6-12	908-911	the	_
6-13	912-918	cortex	_
6-14	919-922	was	_
6-15	923-931	measured	_
6-16	932-934	by	_
6-17	935-943	applying	_
6-18	944-963	psychophysiological	_
6-19	964-975	interaction	_
6-20	976-984	analysis	_
6-21	985-987	to	_
6-22	988-1001	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
6-23	1002-1012	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
6-24	1013-1021	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
6-25	1022-1031	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
6-26	1032-1039	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
6-27	1040-1044	data	_
6-28	1045-1047	of	_
6-29	1048-1050	50	_
6-30	1051-1059	patients	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
6-31	1060-1064	with	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
6-32	1065-1070	first	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
6-33	1071-1078	episode	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
6-34	1079-1092	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
6-35	1093-1094	(	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
6-36	1095-1098	FES	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
6-37	1099-1100	)	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
6-38	1101-1102	,	_
6-39	1103-1105	50	_
6-40	1106-1114	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
6-41	1115-1119	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
6-42	1120-1123	MDD	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
6-43	1124-1125	,	_
6-44	1126-1128	50	_
6-45	1129-1137	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
6-46	1138-1142	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
6-47	1143-1147	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
6-48	1148-1151	and	_
6-49	1152-1155	122	_
6-50	1156-1163	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
6-51	1164-1172	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
6-52	1173-1174	.	_

Text=All participants were medication-naïve.
7-1	1175-1178	All	_
7-2	1179-1191	participants	_
7-3	1192-1196	were	_
7-4	1197-1213	medication-naïve	_
7-5	1214-1215	.	_

Text=The only significant schizophrenia-specific effect was increased EC between the right MDN and the right pallidum (p <0.05 corrected).
8-1	1216-1219	The	_
8-2	1220-1224	only	_
8-3	1225-1236	significant	_
8-4	1237-1259	schizophrenia-specific	_
8-5	1260-1266	effect	_
8-6	1267-1270	was	_
8-7	1271-1280	increased	_
8-8	1281-1283	EC	_
8-9	1284-1291	between	_
8-10	1292-1295	the	_
8-11	1296-1301	right	_
8-12	1302-1305	MDN	_
8-13	1306-1309	and	_
8-14	1310-1313	the	_
8-15	1314-1319	right	_
8-16	1320-1328	pallidum	_
8-17	1329-1330	(	_
8-18	1331-1332	p	_
8-19	1333-1334	<	_
8-20	1335-1339	0.05	_
8-21	1340-1349	corrected	_
8-22	1350-1351	)	_
8-23	1352-1353	.	_

Text=In contrast, there were a number of significant trans-diagnostic alterations, with both right and left MDN displaying trans-diagnostic increased EC with several prefrontal and parietal regions bilaterally (p <0.05 corrected).
9-1	1354-1356	In	_
9-2	1357-1365	contrast	_
9-3	1366-1367	,	_
9-4	1368-1373	there	_
9-5	1374-1378	were	_
9-6	1379-1380	a	_
9-7	1381-1387	number	_
9-8	1388-1390	of	_
9-9	1391-1402	significant	_
9-10	1403-1419	trans-diagnostic	_
9-11	1420-1431	alterations	_
9-12	1432-1433	,	_
9-13	1434-1438	with	_
9-14	1439-1443	both	_
9-15	1444-1449	right	_
9-16	1450-1453	and	_
9-17	1454-1458	left	_
9-18	1459-1462	MDN	_
9-19	1463-1473	displaying	_
9-20	1474-1490	trans-diagnostic	_
9-21	1491-1500	increased	_
9-22	1501-1503	EC	_
9-23	1504-1508	with	_
9-24	1509-1516	several	_
9-25	1517-1527	prefrontal	_
9-26	1528-1531	and	_
9-27	1532-1540	parietal	_
9-28	1541-1548	regions	_
9-29	1549-1560	bilaterally	_
9-30	1561-1562	(	_
9-31	1563-1564	p	_
9-32	1565-1566	<	_
9-33	1567-1571	0.05	_
9-34	1572-1581	corrected	_
9-35	1582-1583	)	_
9-36	1584-1585	.	_

Text=EC alterations between the MDN and the cortex are not specific to schizophrenia but are a trans-diagnostic feature of psychiatric disorders, consistent with emerging conceptualizations of mental illness based on a single general psychopathology factor.
10-1	1586-1588	EC	_
10-2	1589-1600	alterations	_
10-3	1601-1608	between	_
10-4	1609-1612	the	_
10-5	1613-1616	MDN	_
10-6	1617-1620	and	_
10-7	1621-1624	the	_
10-8	1625-1631	cortex	_
10-9	1632-1635	are	_
10-10	1636-1639	not	_
10-11	1640-1648	specific	_
10-12	1649-1651	to	_
10-13	1652-1665	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-14	1666-1669	but	_
10-15	1670-1673	are	_
10-16	1674-1675	a	_
10-17	1676-1692	trans-diagnostic	_
10-18	1693-1700	feature	_
10-19	1701-1703	of	_
10-20	1704-1715	psychiatric	_
10-21	1716-1725	disorders	_
10-22	1726-1727	,	_
10-23	1728-1738	consistent	_
10-24	1739-1743	with	_
10-25	1744-1752	emerging	_
10-26	1753-1771	conceptualizations	_
10-27	1772-1774	of	_
10-28	1775-1781	mental	_
10-29	1782-1789	illness	_
10-30	1790-1795	based	_
10-31	1796-1798	on	_
10-32	1799-1800	a	_
10-33	1801-1807	single	_
10-34	1808-1815	general	_
10-35	1816-1831	psychopathology	_
10-36	1832-1838	factor	_
10-37	1839-1840	.	_

Text=Therefore, dysconnectivity of the MDN could potentially be used to assess the presence of general psychopathology above and beyond traditional diagnostic boundaries.
11-1	1841-1850	Therefore	_
11-2	1851-1852	,	_
11-3	1853-1868	dysconnectivity	_
11-4	1869-1871	of	_
11-5	1872-1875	the	_
11-6	1876-1879	MDN	_
11-7	1880-1885	could	_
11-8	1886-1897	potentially	_
11-9	1898-1900	be	_
11-10	1901-1905	used	_
11-11	1906-1908	to	_
11-12	1909-1915	assess	_
11-13	1916-1919	the	_
11-14	1920-1928	presence	_
11-15	1929-1931	of	_
11-16	1932-1939	general	_
11-17	1940-1955	psychopathology	_
11-18	1956-1961	above	_
11-19	1962-1965	and	_
11-20	1966-1972	beyond	_
11-21	1973-1984	traditional	_
11-22	1985-1995	diagnostic	_
11-23	1996-2006	boundaries	_
11-24	2007-2008	.	_

Text=Materials and methods Participants The study was approved by the Medical Ethics Committee of West China Hospital of Sichuan University and all participants provided written informed consent.
12-1	2009-2018	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
12-2	2019-2022	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
12-3	2023-2030	methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
12-4	2031-2043	Participants	_
12-5	2044-2047	The	_
12-6	2048-2053	study	_
12-7	2054-2057	was	_
12-8	2058-2066	approved	_
12-9	2067-2069	by	_
12-10	2070-2073	the	_
12-11	2074-2081	Medical	_
12-12	2082-2088	Ethics	_
12-13	2089-2098	Committee	_
12-14	2099-2101	of	_
12-15	2102-2106	West	_
12-16	2107-2112	China	_
12-17	2113-2121	Hospital	_
12-18	2122-2124	of	_
12-19	2125-2132	Sichuan	_
12-20	2133-2143	University	_
12-21	2144-2147	and	_
12-22	2148-2151	all	_
12-23	2152-2164	participants	_
12-24	2165-2173	provided	_
12-25	2174-2181	written	_
12-26	2182-2190	informed	_
12-27	2191-2198	consent	_
12-28	2199-2200	.	_

Text=Subsets of the data used here have been used in previous studies.
13-1	2201-2208	Subsets	_
13-2	2209-2211	of	_
13-3	2212-2215	the	_
13-4	2216-2220	data	_
13-5	2221-2225	used	_
13-6	2226-2230	here	_
13-7	2231-2235	have	_
13-8	2236-2240	been	_
13-9	2241-2245	used	_
13-10	2246-2248	in	_
13-11	2249-2257	previous	_
13-12	2258-2265	studies	_
13-13	2266-2267	.	_

Text=While in a recent article we consider functional integration within and between three networks of interest (default mode, central exectutive, and salience), in the present investigation we focus on the EC between the MDN and the cortex.
14-1	2268-2273	While	_
14-2	2274-2276	in	_
14-3	2277-2278	a	_
14-4	2279-2285	recent	_
14-5	2286-2293	article	_
14-6	2294-2296	we	_
14-7	2297-2305	consider	_
14-8	2306-2316	functional	_
14-9	2317-2328	integration	_
14-10	2329-2335	within	_
14-11	2336-2339	and	_
14-12	2340-2347	between	_
14-13	2348-2353	three	_
14-14	2354-2362	networks	_
14-15	2363-2365	of	_
14-16	2366-2374	interest	_
14-17	2375-2376	(	_
14-18	2377-2384	default	_
14-19	2385-2389	mode	_
14-20	2390-2391	,	_
14-21	2392-2399	central	_
14-22	2400-2410	exectutive	_
14-23	2411-2412	,	_
14-24	2413-2416	and	_
14-25	2417-2425	salience	_
14-26	2426-2427	)	_
14-27	2428-2429	,	_
14-28	2430-2432	in	_
14-29	2433-2436	the	_
14-30	2437-2444	present	_
14-31	2445-2458	investigation	_
14-32	2459-2461	we	_
14-33	2462-2467	focus	_
14-34	2468-2470	on	_
14-35	2471-2474	the	_
14-36	2475-2477	EC	_
14-37	2478-2485	between	_
14-38	2486-2489	the	_
14-39	2490-2493	MDN	_
14-40	2494-2497	and	_
14-41	2498-2501	the	_
14-42	2502-2508	cortex	_
14-43	2509-2510	.	_

Text=All patients were recruited as they presented to the West China Hospital of Sichuan University, and were came from the inner city of Chengdu with the exception of the PTSD group who tended to come from surrounding rural areas (see below) Exclusion criteria applicable to all participants included (i) history of drug or alcohol abuse, (ii) pregnancy and (iii) any physical illness such as hepatitis, cardiovascular disease, or neurological disorder, as assessed by interview and review of medical records.
15-1	2511-2514	All	_
15-2	2515-2523	patients	_
15-3	2524-2528	were	_
15-4	2529-2538	recruited	_
15-5	2539-2541	as	_
15-6	2542-2546	they	_
15-7	2547-2556	presented	_
15-8	2557-2559	to	_
15-9	2560-2563	the	_
15-10	2564-2568	West	_
15-11	2569-2574	China	_
15-12	2575-2583	Hospital	_
15-13	2584-2586	of	_
15-14	2587-2594	Sichuan	_
15-15	2595-2605	University	_
15-16	2606-2607	,	_
15-17	2608-2611	and	_
15-18	2612-2616	were	_
15-19	2617-2621	came	_
15-20	2622-2626	from	_
15-21	2627-2630	the	_
15-22	2631-2636	inner	_
15-23	2637-2641	city	_
15-24	2642-2644	of	_
15-25	2645-2652	Chengdu	_
15-26	2653-2657	with	_
15-27	2658-2661	the	_
15-28	2662-2671	exception	_
15-29	2672-2674	of	_
15-30	2675-2678	the	_
15-31	2679-2683	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder
15-32	2684-2689	group	_
15-33	2690-2693	who	_
15-34	2694-2700	tended	_
15-35	2701-2703	to	_
15-36	2704-2708	come	_
15-37	2709-2713	from	_
15-38	2714-2725	surrounding	_
15-39	2726-2731	rural	_
15-40	2732-2737	areas	_
15-41	2738-2739	(	_
15-42	2740-2743	see	_
15-43	2744-2749	below	_
15-44	2750-2751	)	_
15-45	2752-2761	Exclusion	_
15-46	2762-2770	criteria	_
15-47	2771-2781	applicable	_
15-48	2782-2784	to	_
15-49	2785-2788	all	_
15-50	2789-2801	participants	_
15-51	2802-2810	included	_
15-52	2811-2812	(	_
15-53	2813-2814	i	_
15-54	2815-2816	)	_
15-55	2817-2824	history	_
15-56	2825-2827	of	_
15-57	2828-2832	drug	_
15-58	2833-2835	or	_
15-59	2836-2843	alcohol	_
15-60	2844-2849	abuse	_
15-61	2850-2851	,	_
15-62	2852-2853	(	_
15-63	2854-2856	ii	_
15-64	2857-2858	)	_
15-65	2859-2868	pregnancy	_
15-66	2869-2872	and	_
15-67	2873-2874	(	_
15-68	2875-2878	iii	_
15-69	2879-2880	)	_
15-70	2881-2884	any	_
15-71	2885-2893	physical	_
15-72	2894-2901	illness	_
15-73	2902-2906	such	_
15-74	2907-2909	as	_
15-75	2910-2919	hepatitis	_
15-76	2920-2921	,	_
15-77	2922-2936	cardiovascular	_
15-78	2937-2944	disease	_
15-79	2945-2946	,	_
15-80	2947-2949	or	_
15-81	2950-2962	neurological	_
15-82	2963-2971	disorder	_
15-83	2972-2973	,	_
15-84	2974-2976	as	_
15-85	2977-2985	assessed	_
15-86	2986-2988	by	_
15-87	2989-2998	interview	_
15-88	2999-3002	and	_
15-89	3003-3009	review	_
15-90	3010-3012	of	_
15-91	3013-3020	medical	_
15-92	3021-3028	records	_
15-93	3029-3030	.	_

Text=Further information on each group are provided below.
16-1	3031-3038	Further	_
16-2	3039-3050	information	_
16-3	3051-3053	on	_
16-4	3054-3058	each	_
16-5	3059-3064	group	_
16-6	3065-3068	are	_
16-7	3069-3077	provided	_
16-8	3078-3083	below	_
16-9	3084-3085	.	_

Text=First episode schizophrenia Fifty patients with FES were included (see Table 1).
17-1	3086-3091	First	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
17-2	3092-3099	episode	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
17-3	3100-3113	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
17-4	3114-3119	Fifty	_
17-5	3120-3128	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
17-6	3129-3133	with	_
17-7	3134-3137	FES	http://maven.renci.org/NeuroBridge/neurobridge#QualityofLifeScale
17-8	3138-3142	were	_
17-9	3143-3151	included	_
17-10	3152-3153	(	_
17-11	3154-3157	see	_
17-12	3158-3163	Table	_
17-13	3164-3165	1	_
17-14	3166-3167	)	_
17-15	3168-3169	.	_

Text=The presence of psychotic illness was determined by the consensus of two experienced psychiatrists using the Structured Interview for the DSM-IV Axis I Disorder, Patient Edition (SCID).
18-1	3170-3173	The	_
18-2	3174-3182	presence	_
18-3	3183-3185	of	_
18-4	3186-3195	psychotic	_
18-5	3196-3203	illness	_
18-6	3204-3207	was	_
18-7	3208-3218	determined	_
18-8	3219-3221	by	_
18-9	3222-3225	the	_
18-10	3226-3235	consensus	_
18-11	3236-3238	of	_
18-12	3239-3242	two	_
18-13	3243-3254	experienced	_
18-14	3255-3268	psychiatrists	_
18-15	3269-3274	using	_
18-16	3275-3278	the	_
18-17	3279-3289	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
18-18	3290-3299	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
18-19	3300-3303	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
18-20	3304-3307	the	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
18-21	3308-3314	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
18-22	3315-3319	Axis	_
18-23	3320-3321	I	_
18-24	3322-3330	Disorder	_
18-25	3331-3332	,	_
18-26	3333-3340	Patient	_
18-27	3341-3348	Edition	_
18-28	3349-3350	(	_
18-29	3351-3355	SCID	_
18-30	3356-3357	)	_
18-31	3358-3359	.	_

Text=Psychopathology was measured on the day of scanning using the Positive and Negative Syndrome Scale (PANSS).
19-1	3360-3375	Psychopathology	_
19-2	3376-3379	was	_
19-3	3380-3388	measured	_
19-4	3389-3391	on	_
19-5	3392-3395	the	_
19-6	3396-3399	day	_
19-7	3400-3402	of	_
19-8	3403-3411	scanning	_
19-9	3412-3417	using	_
19-10	3418-3421	the	_
19-11	3422-3430	Positive	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
19-12	3431-3434	and	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
19-13	3435-3443	Negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
19-14	3444-3452	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
19-15	3453-3458	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
19-16	3459-3460	(	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
19-17	3461-3466	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
19-18	3467-3468	)	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
19-19	3469-3470	.	_

Text=The use of these clinical instruments indicated that all patients met criteria for schizophrenia—a diagnosis that was confirmed in subsequent clinical follow-ups.
20-1	3471-3474	The	_
20-2	3475-3478	use	_
20-3	3479-3481	of	_
20-4	3482-3487	these	_
20-5	3488-3496	clinical	_
20-6	3497-3508	instruments	_
20-7	3509-3518	indicated	_
20-8	3519-3523	that	_
20-9	3524-3527	all	_
20-10	3528-3536	patients	_
20-11	3537-3540	met	_
20-12	3541-3549	criteria	_
20-13	3550-3553	for	_
20-14	3554-3569	schizophrenia—a	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
20-15	3570-3579	diagnosis	_
20-16	3580-3584	that	_
20-17	3585-3588	was	_
20-18	3589-3598	confirmed	_
20-19	3599-3601	in	_
20-20	3602-3612	subsequent	_
20-21	3613-3621	clinical	_
20-22	3622-3632	follow-ups	_
20-23	3633-3634	.	_

Text=At the time of scanning, all patients were medication-naïve.
21-1	3635-3637	At	_
21-2	3638-3641	the	_
21-3	3642-3646	time	_
21-4	3647-3649	of	_
21-5	3650-3658	scanning	_
21-6	3659-3660	,	_
21-7	3661-3664	all	_
21-8	3665-3673	patients	_
21-9	3674-3678	were	_
21-10	3679-3695	medication-naïve	_
21-11	3696-3697	.	_

Text=Major depressive disorder Fifty participants with MDD were included (see Table 1).
22-1	3698-3703	Major	_
22-2	3704-3714	depressive	_
22-3	3715-3723	disorder	_
22-4	3724-3729	Fifty	_
22-5	3730-3742	participants	_
22-6	3743-3747	with	_
22-7	3748-3751	MDD	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
22-8	3752-3756	were	_
22-9	3757-3765	included	_
22-10	3766-3767	(	_
22-11	3768-3771	see	_
22-12	3772-3777	Table	_
22-13	3778-3779	1	_
22-14	3780-3781	)	_
22-15	3782-3783	.	_

Text=These participants were part of a larger cohort study of depression in the Chinese population of Han nationality.
23-1	3784-3789	These	_
23-2	3790-3802	participants	_
23-3	3803-3807	were	_
23-4	3808-3812	part	_
23-5	3813-3815	of	_
23-6	3816-3817	a	_
23-7	3818-3824	larger	_
23-8	3825-3831	cohort	_
23-9	3832-3837	study	_
23-10	3838-3840	of	_
23-11	3841-3851	depression	_
23-12	3852-3854	in	_
23-13	3855-3858	the	_
23-14	3859-3866	Chinese	_
23-15	3867-3877	population	_
23-16	3878-3880	of	_
23-17	3881-3884	Han	_
23-18	3885-3896	nationality	_
23-19	3897-3898	.	_

Text=Diagnosis of MDD was made with the SCID; although psychotic symptoms can occur during depressive episodes, none of the participants reported suffering from them.
24-1	3899-3908	Diagnosis	_
24-2	3909-3911	of	_
24-3	3912-3915	MDD	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
24-4	3916-3919	was	_
24-5	3920-3924	made	_
24-6	3925-3929	with	_
24-7	3930-3933	the	_
24-8	3934-3938	SCID	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
24-9	3939-3940	;	_
24-10	3941-3949	although	_
24-11	3950-3959	psychotic	_
24-12	3960-3968	symptoms	_
24-13	3969-3972	can	_
24-14	3973-3978	occur	_
24-15	3979-3985	during	_
24-16	3986-3996	depressive	_
24-17	3997-4005	episodes	_
24-18	4006-4007	,	_
24-19	4008-4012	none	_
24-20	4013-4015	of	_
24-21	4016-4019	the	_
24-22	4020-4032	participants	_
24-23	4033-4041	reported	_
24-24	4042-4051	suffering	_
24-25	4052-4056	from	_
24-26	4057-4061	them	_
24-27	4062-4063	.	_

Text=On the day of scanning, severity of depression was quantified using the 17-item Hamilton depression rating scale (HAM-D) and all participants had a total HAM-D score ≥18.
25-1	4064-4066	On	_
25-2	4067-4070	the	_
25-3	4071-4074	day	_
25-4	4075-4077	of	_
25-5	4078-4086	scanning	_
25-6	4087-4088	,	_
25-7	4089-4097	severity	_
25-8	4098-4100	of	_
25-9	4101-4111	depression	_
25-10	4112-4115	was	_
25-11	4116-4126	quantified	_
25-12	4127-4132	using	_
25-13	4133-4136	the	_
25-14	4137-4144	17-item	_
25-15	4145-4153	Hamilton	http://maven.renci.org/NeuroBridge/neurobridge#DepressionRatingScale
25-16	4154-4164	depression	http://maven.renci.org/NeuroBridge/neurobridge#DepressionRatingScale
25-17	4165-4171	rating	http://maven.renci.org/NeuroBridge/neurobridge#DepressionRatingScale
25-18	4172-4177	scale	http://maven.renci.org/NeuroBridge/neurobridge#DepressionRatingScale
25-19	4178-4179	(	http://maven.renci.org/NeuroBridge/neurobridge#DepressionRatingScale
25-20	4180-4185	HAM-D	http://maven.renci.org/NeuroBridge/neurobridge#DepressionRatingScale
25-21	4186-4187	)	http://maven.renci.org/NeuroBridge/neurobridge#DepressionRatingScale
25-22	4188-4191	and	_
25-23	4192-4195	all	_
25-24	4196-4208	participants	_
25-25	4209-4212	had	_
25-26	4213-4214	a	_
25-27	4215-4220	total	_
25-28	4221-4226	HAM-D	_
25-29	4227-4232	score	_
25-30	4233-4236	≥18	_
25-31	4237-4238	.	_

Text=All patients were medication-naïve at the time of scanning.
26-1	4239-4242	All	_
26-2	4243-4251	patients	_
26-3	4252-4256	were	_
26-4	4257-4273	medication-naïve	_
26-5	4274-4276	at	_
26-6	4277-4280	the	_
26-7	4281-4285	time	_
26-8	4286-4288	of	_
26-9	4289-4297	scanning	_
26-10	4298-4299	.	_

Text=Post-traumatic stress disorder Fifty participants with PTSD were included (see Table 1).
27-1	4300-4314	Post-traumatic	_
27-2	4315-4321	stress	_
27-3	4322-4330	disorder	_
27-4	4331-4336	Fifty	_
27-5	4337-4349	participants	http://maven.renci.org/NeuroBridge/neurobridge#SubjectwithoutDisorder
27-6	4350-4354	with	http://maven.renci.org/NeuroBridge/neurobridge#SubjectwithoutDisorder
27-7	4355-4359	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder
27-8	4360-4364	were	_
27-9	4365-4373	included	_
27-10	4374-4375	(	_
27-11	4376-4379	see	_
27-12	4380-4385	Table	_
27-13	4386-4387	1	_
27-14	4388-4389	)	_
27-15	4390-4391	.	_

Text=These participants were survivors of the 2008 Sichuan earthquake who lived in rural areas, had all physically experienced the earthquake, personally witnessed death, serious injury or the collapse of buildings and not suffered any physical injury; because these patients were recruited in the aftermath of the earthquake, they came from rural areas (where the Earthquake was strongest) and were older relative to the other clinical groups.
28-1	4392-4397	These	_
28-2	4398-4410	participants	_
28-3	4411-4415	were	_
28-4	4416-4425	survivors	_
28-5	4426-4428	of	_
28-6	4429-4432	the	_
28-7	4433-4437	2008	_
28-8	4438-4445	Sichuan	_
28-9	4446-4456	earthquake	_
28-10	4457-4460	who	_
28-11	4461-4466	lived	_
28-12	4467-4469	in	_
28-13	4470-4475	rural	_
28-14	4476-4481	areas	_
28-15	4482-4483	,	_
28-16	4484-4487	had	_
28-17	4488-4491	all	_
28-18	4492-4502	physically	_
28-19	4503-4514	experienced	_
28-20	4515-4518	the	_
28-21	4519-4529	earthquake	_
28-22	4530-4531	,	_
28-23	4532-4542	personally	_
28-24	4543-4552	witnessed	_
28-25	4553-4558	death	_
28-26	4559-4560	,	_
28-27	4561-4568	serious	_
28-28	4569-4575	injury	_
28-29	4576-4578	or	_
28-30	4579-4582	the	_
28-31	4583-4591	collapse	_
28-32	4592-4594	of	_
28-33	4595-4604	buildings	_
28-34	4605-4608	and	_
28-35	4609-4612	not	_
28-36	4613-4621	suffered	_
28-37	4622-4625	any	_
28-38	4626-4634	physical	_
28-39	4635-4641	injury	_
28-40	4642-4643	;	_
28-41	4644-4651	because	_
28-42	4652-4657	these	_
28-43	4658-4666	patients	_
28-44	4667-4671	were	_
28-45	4672-4681	recruited	_
28-46	4682-4684	in	_
28-47	4685-4688	the	_
28-48	4689-4698	aftermath	_
28-49	4699-4701	of	_
28-50	4702-4705	the	_
28-51	4706-4716	earthquake	_
28-52	4717-4718	,	_
28-53	4719-4723	they	_
28-54	4724-4728	came	_
28-55	4729-4733	from	_
28-56	4734-4739	rural	_
28-57	4740-4745	areas	_
28-58	4746-4747	(	_
28-59	4748-4753	where	_
28-60	4754-4757	the	_
28-61	4758-4768	Earthquake	_
28-62	4769-4772	was	_
28-63	4773-4782	strongest	_
28-64	4783-4784	)	_
28-65	4785-4788	and	_
28-66	4789-4793	were	_
28-67	4794-4799	older	_
28-68	4800-4808	relative	_
28-69	4809-4811	to	_
28-70	4812-4815	the	_
28-71	4816-4821	other	_
28-72	4822-4830	clinical	_
28-73	4831-4837	groups	_
28-74	4838-4839	.	_

Text=All participants were assessed using the PTSD Checklist (PCL) and met threshold criteria (PCL score ≥ 35) for diagnosis of PTSD on the day of scanning.
29-1	4840-4843	All	_
29-2	4844-4856	participants	_
29-3	4857-4861	were	_
29-4	4862-4870	assessed	_
29-5	4871-4876	using	_
29-6	4877-4880	the	_
29-7	4881-4885	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#Thermistor
29-8	4886-4895	Checklist	http://maven.renci.org/NeuroBridge/neurobridge#Thermistor
29-9	4896-4897	(	http://maven.renci.org/NeuroBridge/neurobridge#Thermistor
29-10	4898-4901	PCL	http://maven.renci.org/NeuroBridge/neurobridge#Thermistor
29-11	4902-4903	)	http://maven.renci.org/NeuroBridge/neurobridge#Thermistor
29-12	4904-4907	and	_
29-13	4908-4911	met	_
29-14	4912-4921	threshold	_
29-15	4922-4930	criteria	_
29-16	4931-4932	(	_
29-17	4933-4936	PCL	_
29-18	4937-4942	score	_
29-19	4943-4944	≥	_
29-20	4945-4947	35	_
29-21	4948-4949	)	_
29-22	4950-4953	for	_
29-23	4954-4963	diagnosis	_
29-24	4964-4966	of	_
29-25	4967-4971	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder
29-26	4972-4974	on	_
29-27	4975-4978	the	_
29-28	4979-4982	day	_
29-29	4983-4985	of	_
29-30	4986-4994	scanning	_
29-31	4995-4996	.	_

Text=At the time of scanning, all patients were medication-naïve.
30-1	4997-4999	At	_
30-2	5000-5003	the	_
30-3	5004-5008	time	_
30-4	5009-5011	of	_
30-5	5012-5020	scanning	_
30-6	5021-5022	,	_
30-7	5023-5026	all	_
30-8	5027-5035	patients	_
30-9	5036-5040	were	_
30-10	5041-5057	medication-naïve	_
30-11	5058-5059	.	_

Text=Healthy controls One hundred and twenty two HC were included (Table 1).
31-1	5060-5067	Healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
31-2	5068-5076	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
31-3	5077-5080	One	_
31-4	5081-5088	hundred	_
31-5	5089-5092	and	_
31-6	5093-5099	twenty	_
31-7	5100-5103	two	_
31-8	5104-5106	HC	_
31-9	5107-5111	were	_
31-10	5112-5120	included	_
31-11	5121-5122	(	_
31-12	5123-5128	Table	_
31-13	5129-5130	1	_
31-14	5131-5132	)	_
31-15	5133-5134	.	_

Text=All were recruited by poster advertisement, and screened using the non-patient edition of the SCID to confirm the lifetime absence of psychiatric illnesses.
32-1	5135-5138	All	_
32-2	5139-5143	were	_
32-3	5144-5153	recruited	_
32-4	5154-5156	by	_
32-5	5157-5163	poster	_
32-6	5164-5177	advertisement	_
32-7	5178-5179	,	_
32-8	5180-5183	and	_
32-9	5184-5192	screened	_
32-10	5193-5198	using	_
32-11	5199-5202	the	_
32-12	5203-5214	non-patient	_
32-13	5215-5222	edition	_
32-14	5223-5225	of	_
32-15	5226-5229	the	_
32-16	5230-5234	SCID	_
32-17	5235-5237	to	_
32-18	5238-5245	confirm	_
32-19	5246-5249	the	_
32-20	5250-5258	lifetime	_
32-21	5259-5266	absence	_
32-22	5267-5269	of	_
32-23	5270-5281	psychiatric	_
32-24	5282-5291	illnesses	_
32-25	5292-5293	.	_

Text=In addition, all were interviewed to exclude individuals with a known history of psychiatric illness in first-degree relatives.
33-1	5294-5296	In	_
33-2	5297-5305	addition	_
33-3	5306-5307	,	_
33-4	5308-5311	all	_
33-5	5312-5316	were	_
33-6	5317-5328	interviewed	_
33-7	5329-5331	to	_
33-8	5332-5339	exclude	_
33-9	5340-5351	individuals	_
33-10	5352-5356	with	_
33-11	5357-5358	a	_
33-12	5359-5364	known	_
33-13	5365-5372	history	_
33-14	5373-5375	of	_
33-15	5376-5387	psychiatric	_
33-16	5388-5395	illness	_
33-17	5396-5398	in	_
33-18	5399-5411	first-degree	_
33-19	5412-5421	relatives	_
33-20	5422-5423	.	_

Text=Data acquisition All neuroimaging data was acquired from a 3T MRI scanner (EXCITE; General Electric, Milwaukee, Wisconsin) with an 8-channel phased array head coil.
34-1	5424-5428	Data	_
34-2	5429-5440	acquisition	_
34-3	5441-5444	All	_
34-4	5445-5457	neuroimaging	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
34-5	5458-5462	data	_
34-6	5463-5466	was	_
34-7	5467-5475	acquired	_
34-8	5476-5480	from	_
34-9	5481-5482	a	_
34-10	5483-5485	3T	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
34-11	5486-5489	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
34-12	5490-5497	scanner	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
34-13	5498-5499	(	_
34-14	5500-5506	EXCITE	_
34-15	5507-5508	;	_
34-16	5509-5516	General	_
34-17	5517-5525	Electric	_
34-18	5526-5527	,	_
34-19	5528-5537	Milwaukee	_
34-20	5538-5539	,	_
34-21	5540-5549	Wisconsin	_
34-22	5550-5551	)	_
34-23	5552-5556	with	_
34-24	5557-5559	an	_
34-25	5560-5569	8-channel	_
34-26	5570-5576	phased	_
34-27	5577-5582	array	_
34-28	5583-5587	head	_
34-29	5588-5592	coil	_
34-30	5593-5594	.	_

Text=Images were acquired using a gradient-echo echo-planar imaging sequence with a repetition time (TR) = 2000 ms, an echo time (TE) = 30 ms, flip-angle = 90°, slice thickness = 5 mm (no slice gap), 64 × 64 matrix and field of view = 24 cm2 resulting in a voxel size of 3.75 × 3.75 × 5 mm3.
35-1	5595-5601	Images	_
35-2	5602-5606	were	_
35-3	5607-5615	acquired	_
35-4	5616-5621	using	_
35-5	5622-5623	a	_
35-6	5624-5637	gradient-echo	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
35-7	5638-5649	echo-planar	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
35-8	5650-5657	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
35-9	5658-5666	sequence	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
35-10	5667-5671	with	_
35-11	5672-5673	a	_
35-12	5674-5684	repetition	_
35-13	5685-5689	time	_
35-14	5690-5691	(	_
35-15	5692-5694	TR	_
35-16	5695-5696	)	_
35-17	5697-5698	=	_
35-18	5699-5703	2000	_
35-19	5704-5706	ms	_
35-20	5707-5708	,	_
35-21	5709-5711	an	_
35-22	5712-5716	echo	_
35-23	5717-5721	time	_
35-24	5722-5723	(	_
35-25	5724-5726	TE	_
35-26	5727-5728	)	_
35-27	5729-5730	=	_
35-28	5731-5733	30	_
35-29	5734-5736	ms	_
35-30	5737-5738	,	_
35-31	5739-5749	flip-angle	_
35-32	5750-5751	=	_
35-33	5752-5755	90°	_
35-34	5756-5757	,	_
35-35	5758-5763	slice	_
35-36	5764-5773	thickness	_
35-37	5774-5775	=	_
35-38	5776-5777	5	_
35-39	5778-5780	mm	_
35-40	5781-5782	(	_
35-41	5783-5785	no	_
35-42	5786-5791	slice	_
35-43	5792-5795	gap	_
35-44	5796-5797	)	_
35-45	5798-5799	,	_
35-46	5800-5802	64	_
35-47	5803-5804	×	_
35-48	5805-5807	64	_
35-49	5808-5814	matrix	_
35-50	5815-5818	and	_
35-51	5819-5824	field	_
35-52	5825-5827	of	_
35-53	5828-5832	view	_
35-54	5833-5834	=	_
35-55	5835-5837	24	_
35-56	5838-5841	cm2	_
35-57	5842-5851	resulting	_
35-58	5852-5854	in	_
35-59	5855-5856	a	_
35-60	5857-5862	voxel	_
35-61	5863-5867	size	_
35-62	5868-5870	of	_
35-63	5871-5875	3.75	_
35-64	5876-5877	×	_
35-65	5878-5882	3.75	_
35-66	5883-5884	×	_
35-67	5885-5886	5	_
35-68	5887-5890	mm3	_
35-69	5891-5892	.	_

Text=Scanning lasted for 410 s, with each brain volume comprising 30 axial slices and each functional run containing 205 image volumes.
36-1	5893-5901	Scanning	_
36-2	5902-5908	lasted	_
36-3	5909-5912	for	_
36-4	5913-5916	410	_
36-5	5917-5918	s	_
36-6	5919-5920	,	_
36-7	5921-5925	with	_
36-8	5926-5930	each	_
36-9	5931-5936	brain	_
36-10	5937-5943	volume	_
36-11	5944-5954	comprising	_
36-12	5955-5957	30	_
36-13	5958-5963	axial	_
36-14	5964-5970	slices	_
36-15	5971-5974	and	_
36-16	5975-5979	each	_
36-17	5980-5990	functional	_
36-18	5991-5994	run	_
36-19	5995-6005	containing	_
36-20	6006-6009	205	_
36-21	6010-6015	image	_
36-22	6016-6023	volumes	_
36-23	6024-6025	.	_

Text=During scanning, participants were instructed to relax with their eyes closed without falling asleep.
37-1	6026-6032	During	_
37-2	6033-6041	scanning	_
37-3	6042-6043	,	_
37-4	6044-6056	participants	_
37-5	6057-6061	were	_
37-6	6062-6072	instructed	_
37-7	6073-6075	to	_
37-8	6076-6081	relax	_
37-9	6082-6086	with	_
37-10	6087-6092	their	_
37-11	6093-6097	eyes	_
37-12	6098-6104	closed	_
37-13	6105-6112	without	_
37-14	6113-6120	falling	_
37-15	6121-6127	asleep	_
37-16	6128-6129	.	_

Text=After the experiment, each participant confirmed as to not having fallen asleep during scanning.
38-1	6130-6135	After	_
38-2	6136-6139	the	_
38-3	6140-6150	experiment	_
38-4	6151-6152	,	_
38-5	6153-6157	each	_
38-6	6158-6169	participant	_
38-7	6170-6179	confirmed	_
38-8	6180-6182	as	_
38-9	6183-6185	to	_
38-10	6186-6189	not	_
38-11	6190-6196	having	_
38-12	6197-6203	fallen	_
38-13	6204-6210	asleep	_
38-14	6211-6217	during	_
38-15	6218-6226	scanning	_
38-16	6227-6228	.	_

Text=Data analysis Preprocessing Functional images were pre-processed using SPM12 software (http: //www.fil.ion.ucl.ac.uk/spm) running under Matlab 7.1 (Math Works, USA).
39-1	6229-6233	Data	_
39-2	6234-6242	analysis	_
39-3	6243-6256	Preprocessing	_
39-4	6257-6267	Functional	_
39-5	6268-6274	images	_
39-6	6275-6279	were	_
39-7	6280-6293	pre-processed	_
39-8	6294-6299	using	_
39-9	6300-6305	SPM12	_
39-10	6306-6314	software	_
39-11	6315-6316	(	_
39-12	6317-6321	http	_
39-13	6322-6323	:	_
39-14	6324-6351	//www.fil.ion.ucl.ac.uk/spm	_
39-15	6352-6353	)	_
39-16	6354-6361	running	_
39-17	6362-6367	under	_
39-18	6368-6374	Matlab	_
39-19	6375-6378	7.1	_
39-20	6379-6380	(	_
39-21	6381-6385	Math	_
39-22	6386-6391	Works	_
39-23	6392-6393	,	_
39-24	6394-6397	USA	_
39-25	6398-6399	)	_
39-26	6400-6401	.	_

Text=For each participant, the first five scans were discarded to remove the impact of magnetization stabilization, and the images were realigned to the first of the run and resliced with sinc interpolation.
40-1	6402-6405	For	_
40-2	6406-6410	each	_
40-3	6411-6422	participant	_
40-4	6423-6424	,	_
40-5	6425-6428	the	_
40-6	6429-6434	first	_
40-7	6435-6439	five	_
40-8	6440-6445	scans	_
40-9	6446-6450	were	_
40-10	6451-6460	discarded	_
40-11	6461-6463	to	_
40-12	6464-6470	remove	_
40-13	6471-6474	the	_
40-14	6475-6481	impact	_
40-15	6482-6484	of	_
40-16	6485-6498	magnetization	_
40-17	6499-6512	stabilization	_
40-18	6513-6514	,	_
40-19	6515-6518	and	_
40-20	6519-6522	the	_
40-21	6523-6529	images	_
40-22	6530-6534	were	_
40-23	6535-6544	realigned	_
40-24	6545-6547	to	_
40-25	6548-6551	the	_
40-26	6552-6557	first	_
40-27	6558-6560	of	_
40-28	6561-6564	the	_
40-29	6565-6568	run	_
40-30	6569-6572	and	_
40-31	6573-6581	resliced	_
40-32	6582-6586	with	_
40-33	6587-6591	sinc	_
40-34	6592-6605	interpolation	_
40-35	6606-6607	.	_

Text=The resulting images were normalized to the Montreal Neurological Institute (MNI) 152 template and then linearly de-trended and band pass filtered (0.01–0.08 Hz) to remove low-frequency drift and high-frequency physiological noise.
41-1	6608-6611	The	_
41-2	6612-6621	resulting	_
41-3	6622-6628	images	_
41-4	6629-6633	were	_
41-5	6634-6644	normalized	_
41-6	6645-6647	to	_
41-7	6648-6651	the	_
41-8	6652-6660	Montreal	_
41-9	6661-6673	Neurological	_
41-10	6674-6683	Institute	_
41-11	6684-6685	(	_
41-12	6686-6689	MNI	_
41-13	6690-6691	)	_
41-14	6692-6695	152	_
41-15	6696-6704	template	_
41-16	6705-6708	and	_
41-17	6709-6713	then	_
41-18	6714-6722	linearly	_
41-19	6723-6733	de-trended	_
41-20	6734-6737	and	_
41-21	6738-6742	band	_
41-22	6743-6747	pass	_
41-23	6748-6756	filtered	_
41-24	6757-6758	(	_
41-25	6759-6768	0.01–0.08	_
41-26	6769-6771	Hz	_
41-27	6772-6773	)	_
41-28	6774-6776	to	_
41-29	6777-6783	remove	_
41-30	6784-6797	low-frequency	_
41-31	6798-6803	drift	_
41-32	6804-6807	and	_
41-33	6808-6822	high-frequency	_
41-34	6823-6836	physiological	_
41-35	6837-6842	noise	_
41-36	6843-6844	.	_

Text=Finally the normalized images were smoothed with an 8-mm full width at half maximum isotropic Gaussian kernel, and the global signal, the white matter signal and the cerebrospinal fluid signal were regressed out.
42-1	6845-6852	Finally	_
42-2	6853-6856	the	_
42-3	6857-6867	normalized	_
42-4	6868-6874	images	_
42-5	6875-6879	were	_
42-6	6880-6888	smoothed	_
42-7	6889-6893	with	_
42-8	6894-6896	an	_
42-9	6897-6901	8-mm	_
42-10	6902-6906	full	_
42-11	6907-6912	width	_
42-12	6913-6915	at	_
42-13	6916-6920	half	_
42-14	6921-6928	maximum	_
42-15	6929-6938	isotropic	_
42-16	6939-6947	Gaussian	_
42-17	6948-6954	kernel	_
42-18	6955-6956	,	_
42-19	6957-6960	and	_
42-20	6961-6964	the	_
42-21	6965-6971	global	_
42-22	6972-6978	signal	_
42-23	6979-6980	,	_
42-24	6981-6984	the	_
42-25	6985-6990	white	_
42-26	6991-6997	matter	_
42-27	6998-7004	signal	_
42-28	7005-7008	and	_
42-29	7009-7012	the	_
42-30	7013-7026	cerebrospinal	_
42-31	7027-7032	fluid	_
42-32	7033-7039	signal	_
42-33	7040-7044	were	_
42-34	7045-7054	regressed	_
42-35	7055-7058	out	_
42-36	7059-7060	.	_

Text=None of the subjects who enrolled on the study had to be excluded due to excessive head motion during scanning (defined as translational movement> 1.5 mm and/or rotation> 1.5°).
43-1	7061-7065	None	_
43-2	7066-7068	of	_
43-3	7069-7072	the	_
43-4	7073-7081	subjects	_
43-5	7082-7085	who	_
43-6	7086-7094	enrolled	_
43-7	7095-7097	on	_
43-8	7098-7101	the	_
43-9	7102-7107	study	_
43-10	7108-7111	had	_
43-11	7112-7114	to	_
43-12	7115-7117	be	_
43-13	7118-7126	excluded	_
43-14	7127-7130	due	_
43-15	7131-7133	to	_
43-16	7134-7143	excessive	_
43-17	7144-7148	head	_
43-18	7149-7155	motion	_
43-19	7156-7162	during	_
43-20	7163-7171	scanning	_
43-21	7172-7173	(	_
43-22	7174-7181	defined	_
43-23	7182-7184	as	_
43-24	7185-7198	translational	_
43-25	7199-7207	movement	_
43-26	7208-7209	>	_
43-27	7210-7213	1.5	_
43-28	7214-7216	mm	_
43-29	7217-7223	and/or	_
43-30	7224-7232	rotation	_
43-31	7233-7234	>	_
43-32	7235-7239	1.5°	_
43-33	7240-7241	)	_
43-34	7242-7243	.	_

Text=In order to test for differences in head movement, we estimated the framewise displacement of each subject—a measure of head movement from one volume to the next calculated as the sum of the absolute values of the realignment estimates at every time point; an ANOVA did not reveal significant differences across the four groups (df = 3, F = 1.903, p = 0.129).
44-1	7244-7246	In	_
44-2	7247-7252	order	_
44-3	7253-7255	to	_
44-4	7256-7260	test	_
44-5	7261-7264	for	_
44-6	7265-7276	differences	_
44-7	7277-7279	in	_
44-8	7280-7284	head	_
44-9	7285-7293	movement	_
44-10	7294-7295	,	_
44-11	7296-7298	we	_
44-12	7299-7308	estimated	_
44-13	7309-7312	the	_
44-14	7313-7322	framewise	_
44-15	7323-7335	displacement	_
44-16	7336-7338	of	_
44-17	7339-7343	each	_
44-18	7344-7353	subject—a	_
44-19	7354-7361	measure	_
44-20	7362-7364	of	_
44-21	7365-7369	head	_
44-22	7370-7378	movement	_
44-23	7379-7383	from	_
44-24	7384-7387	one	_
44-25	7388-7394	volume	_
44-26	7395-7397	to	_
44-27	7398-7401	the	_
44-28	7402-7406	next	_
44-29	7407-7417	calculated	_
44-30	7418-7420	as	_
44-31	7421-7424	the	_
44-32	7425-7428	sum	_
44-33	7429-7431	of	_
44-34	7432-7435	the	_
44-35	7436-7444	absolute	_
44-36	7445-7451	values	_
44-37	7452-7454	of	_
44-38	7455-7458	the	_
44-39	7459-7470	realignment	_
44-40	7471-7480	estimates	_
44-41	7481-7483	at	_
44-42	7484-7489	every	_
44-43	7490-7494	time	_
44-44	7495-7500	point	_
44-45	7501-7502	;	_
44-46	7503-7505	an	_
44-47	7506-7511	ANOVA	_
44-48	7512-7515	did	_
44-49	7516-7519	not	_
44-50	7520-7526	reveal	_
44-51	7527-7538	significant	_
44-52	7539-7550	differences	_
44-53	7551-7557	across	_
44-54	7558-7561	the	_
44-55	7562-7566	four	_
44-56	7567-7573	groups	_
44-57	7574-7575	(	_
44-58	7576-7578	df	_
44-59	7579-7580	=	_
44-60	7581-7582	3	_
44-61	7583-7584	,	_
44-62	7585-7586	F	_
44-63	7587-7588	=	_
44-64	7589-7594	1.903	_
44-65	7595-7596	,	_
44-66	7597-7598	p	_
44-67	7599-7600	=	_
44-68	7601-7606	0.129	_
44-69	7607-7608	)	_
44-70	7609-7610	.	_

Text=Psychophysiological interaction analysis Psychophysiological interaction analysis was conducted using SPM12 software running under MATLAB 8.6.
45-1	7611-7630	Psychophysiological	_
45-2	7631-7642	interaction	_
45-3	7643-7651	analysis	_
45-4	7652-7671	Psychophysiological	_
45-5	7672-7683	interaction	_
45-6	7684-7692	analysis	_
45-7	7693-7696	was	_
45-8	7697-7706	conducted	_
45-9	7707-7712	using	_
45-10	7713-7718	SPM12	_
45-11	7719-7727	software	_
45-12	7728-7735	running	_
45-13	7736-7741	under	_
45-14	7742-7748	MATLAB	_
45-15	7749-7752	8.6	_
45-16	7753-7754	.	_

Text=Firstly, the left and right MDN were selected as regions of interest and anatomically identified using the Talairach Daemon Brodmann Areas + atlas on WFU_PickAtlas 3.0.5 software.
46-1	7755-7762	Firstly	_
46-2	7763-7764	,	_
46-3	7765-7768	the	_
46-4	7769-7773	left	_
46-5	7774-7777	and	_
46-6	7778-7783	right	_
46-7	7784-7787	MDN	_
46-8	7788-7792	were	_
46-9	7793-7801	selected	_
46-10	7802-7804	as	_
46-11	7805-7812	regions	_
46-12	7813-7815	of	_
46-13	7816-7824	interest	_
46-14	7825-7828	and	_
46-15	7829-7841	anatomically	_
46-16	7842-7852	identified	_
46-17	7853-7858	using	_
46-18	7859-7862	the	_
46-19	7863-7872	Talairach	_
46-20	7873-7879	Daemon	_
46-21	7880-7888	Brodmann	_
46-22	7889-7894	Areas	_
46-23	7895-7896	+	_
46-24	7897-7902	atlas	_
46-25	7903-7905	on	_
46-26	7906-7919	WFU_PickAtlas	_
46-27	7920-7925	3.0.5	_
46-28	7926-7934	software	_
46-29	7935-7936	.	_

Text=The left MDN centered on (−6.15, −17, 7.85; MNI co-ordinates) and the right MDN centered on (6.31, −17, 7.85).
47-1	7937-7940	The	_
47-2	7941-7945	left	_
47-3	7946-7949	MDN	_
47-4	7950-7958	centered	_
47-5	7959-7961	on	_
47-6	7962-7963	(	_
47-7	7964-7969	−6.15	_
47-8	7970-7971	,	_
47-9	7972-7975	−17	_
47-10	7976-7977	,	_
47-11	7978-7982	7.85	_
47-12	7983-7984	;	_
47-13	7985-7988	MNI	_
47-14	7989-8001	co-ordinates	_
47-15	8002-8003	)	_
47-16	8004-8007	and	_
47-17	8008-8011	the	_
47-18	8012-8017	right	_
47-19	8018-8021	MDN	_
47-20	8022-8030	centered	_
47-21	8031-8033	on	_
47-22	8034-8035	(	_
47-23	8036-8040	6.31	_
47-24	8041-8042	,	_
47-25	8043-8046	−17	_
47-26	8047-8048	,	_
47-27	8049-8053	7.85	_
47-28	8054-8055	)	_
47-29	8056-8057	.	_

Text=The raw mean time-series of voxels in each region of interest were then extracted for each subject using the MarsBaR toolbox for SPM.
48-1	8058-8061	The	_
48-2	8062-8065	raw	_
48-3	8066-8070	mean	_
48-4	8071-8082	time-series	_
48-5	8083-8085	of	_
48-6	8086-8092	voxels	_
48-7	8093-8095	in	_
48-8	8096-8100	each	_
48-9	8101-8107	region	_
48-10	8108-8110	of	_
48-11	8111-8119	interest	_
48-12	8120-8124	were	_
48-13	8125-8129	then	_
48-14	8130-8139	extracted	_
48-15	8140-8143	for	_
48-16	8144-8148	each	_
48-17	8149-8156	subject	_
48-18	8157-8162	using	_
48-19	8163-8166	the	_
48-20	8167-8174	MarsBaR	_
48-21	8175-8182	toolbox	_
48-22	8183-8186	for	_
48-23	8187-8190	SPM	_
48-24	8191-8192	.	_

Text=For each subject, the extracted values were correlated with all other voxels in the brain using linear regression with the subject head motion parameters modeled as co-variates of no interest.
49-1	8193-8196	For	_
49-2	8197-8201	each	_
49-3	8202-8209	subject	_
49-4	8210-8211	,	_
49-5	8212-8215	the	_
49-6	8216-8225	extracted	_
49-7	8226-8232	values	_
49-8	8233-8237	were	_
49-9	8238-8248	correlated	_
49-10	8249-8253	with	_
49-11	8254-8257	all	_
49-12	8258-8263	other	_
49-13	8264-8270	voxels	_
49-14	8271-8273	in	_
49-15	8274-8277	the	_
49-16	8278-8283	brain	_
49-17	8284-8289	using	_
49-18	8290-8296	linear	_
49-19	8297-8307	regression	_
49-20	8308-8312	with	_
49-21	8313-8316	the	_
49-22	8317-8324	subject	_
49-23	8325-8329	head	_
49-24	8330-8336	motion	_
49-25	8337-8347	parameters	_
49-26	8348-8355	modeled	_
49-27	8356-8358	as	_
49-28	8359-8370	co-variates	_
49-29	8371-8373	of	_
49-30	8374-8376	no	_
49-31	8377-8385	interest	_
49-32	8386-8387	.	_

Text=Subject-level t-contrast maps were combined into a group-level analysis of variance (ANOVA) with age and gender modeled as covariates of no interest.
50-1	8388-8401	Subject-level	_
50-2	8402-8412	t-contrast	_
50-3	8413-8417	maps	_
50-4	8418-8422	were	_
50-5	8423-8431	combined	_
50-6	8432-8436	into	_
50-7	8437-8438	a	_
50-8	8439-8450	group-level	_
50-9	8451-8459	analysis	_
50-10	8460-8462	of	_
50-11	8463-8471	variance	_
50-12	8472-8473	(	_
50-13	8474-8479	ANOVA	_
50-14	8480-8481	)	_
50-15	8482-8486	with	_
50-16	8487-8490	age	_
50-17	8491-8494	and	_
50-18	8495-8501	gender	_
50-19	8502-8509	modeled	_
50-20	8510-8512	as	_
50-21	8513-8523	covariates	_
50-22	8524-8526	of	_
50-23	8527-8529	no	_
50-24	8530-8538	interest	_
50-25	8539-8540	.	_

Text=Effectively, this seed-based approach conforms to a psychophysiological interaction analysis.
51-1	8541-8552	Effectively	_
51-2	8553-8554	,	_
51-3	8555-8559	this	_
51-4	8560-8570	seed-based	_
51-5	8571-8579	approach	_
51-6	8580-8588	conforms	_
51-7	8589-8591	to	_
51-8	8592-8593	a	_
51-9	8594-8613	psychophysiological	_
51-10	8614-8625	interaction	_
51-11	8626-8634	analysis	_
51-12	8635-8636	.	_

Text=In other words, we use the regression slope of activity in any given voxel on activity in the (thalamic) seed region as a measure of direct (linear) coupling and then compared this measure between diagnostic groups.
52-1	8637-8639	In	_
52-2	8640-8645	other	_
52-3	8646-8651	words	_
52-4	8652-8653	,	_
52-5	8654-8656	we	_
52-6	8657-8660	use	_
52-7	8661-8664	the	_
52-8	8665-8675	regression	_
52-9	8676-8681	slope	_
52-10	8682-8684	of	_
52-11	8685-8693	activity	_
52-12	8694-8696	in	_
52-13	8697-8700	any	_
52-14	8701-8706	given	_
52-15	8707-8712	voxel	_
52-16	8713-8715	on	_
52-17	8716-8724	activity	_
52-18	8725-8727	in	_
52-19	8728-8731	the	_
52-20	8732-8733	(	_
52-21	8734-8742	thalamic	_
52-22	8743-8744	)	_
52-23	8745-8749	seed	_
52-24	8750-8756	region	_
52-25	8757-8759	as	_
52-26	8760-8761	a	_
52-27	8762-8769	measure	_
52-28	8770-8772	of	_
52-29	8773-8779	direct	_
52-30	8780-8781	(	_
52-31	8782-8788	linear	_
52-32	8789-8790	)	_
52-33	8791-8799	coupling	_
52-34	8800-8803	and	_
52-35	8804-8808	then	_
52-36	8809-8817	compared	_
52-37	8818-8822	this	_
52-38	8823-8830	measure	_
52-39	8831-8838	between	_
52-40	8839-8849	diagnostic	_
52-41	8850-8856	groups	_
52-42	8857-8858	.	_

Text=This psychophysiological interaction analysis has the advantage of not conflating coupling with the amplitude of error terms—a recognized methodological issue in the statistical analysis of (Z-transformed) functional correlation measures.
53-1	8859-8863	This	_
53-2	8864-8883	psychophysiological	_
53-3	8884-8895	interaction	_
53-4	8896-8904	analysis	_
53-5	8905-8908	has	_
53-6	8909-8912	the	_
53-7	8913-8922	advantage	_
53-8	8923-8925	of	_
53-9	8926-8929	not	_
53-10	8930-8940	conflating	_
53-11	8941-8949	coupling	_
53-12	8950-8954	with	_
53-13	8955-8958	the	_
53-14	8959-8968	amplitude	_
53-15	8969-8971	of	_
53-16	8972-8977	error	_
53-17	8978-8985	terms—a	_
53-18	8986-8996	recognized	_
53-19	8997-9011	methodological	_
53-20	9012-9017	issue	_
53-21	9018-9020	in	_
53-22	9021-9024	the	_
53-23	9025-9036	statistical	_
53-24	9037-9045	analysis	_
53-25	9046-9048	of	_
53-26	9049-9050	(	_
53-27	9051-9064	Z-transformed	_
53-28	9065-9066	)	_
53-29	9067-9077	functional	_
53-30	9078-9089	correlation	_
53-31	9090-9098	measures	_
53-32	9099-9100	.	_

Text=Alterations specific to schizophrenia were identified by comparing this group against the other three groups (e.g., schizophrenia vs. HC, PTSD, and MDD) and then using the inclusive masking option (at p <0.05 uncorrected) in SPM12 software to identify those regions that survived the individual comparisons (i.e., schizophrenia vs. HC; schizophrenia vs. PTSD; schizophrenia vs. MDD).
54-1	9101-9112	Alterations	_
54-2	9113-9121	specific	_
54-3	9122-9124	to	_
54-4	9125-9138	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
54-5	9139-9143	were	_
54-6	9144-9154	identified	_
54-7	9155-9157	by	_
54-8	9158-9167	comparing	_
54-9	9168-9172	this	_
54-10	9173-9178	group	_
54-11	9179-9186	against	_
54-12	9187-9190	the	_
54-13	9191-9196	other	_
54-14	9197-9202	three	_
54-15	9203-9209	groups	_
54-16	9210-9211	(	_
54-17	9212-9216	e.g.	_
54-18	9217-9218	,	_
54-19	9219-9232	schizophrenia	_
54-20	9233-9236	vs.	_
54-21	9237-9239	HC	_
54-22	9240-9241	,	_
54-23	9242-9246	PTSD	_
54-24	9247-9248	,	_
54-25	9249-9252	and	_
54-26	9253-9256	MDD	_
54-27	9257-9258	)	_
54-28	9259-9262	and	_
54-29	9263-9267	then	_
54-30	9268-9273	using	_
54-31	9274-9277	the	_
54-32	9278-9287	inclusive	_
54-33	9288-9295	masking	_
54-34	9296-9302	option	_
54-35	9303-9304	(	_
54-36	9305-9307	at	_
54-37	9308-9309	p	_
54-38	9310-9311	<	_
54-39	9312-9316	0.05	_
54-40	9317-9328	uncorrected	_
54-41	9329-9330	)	_
54-42	9331-9333	in	_
54-43	9334-9339	SPM12	_
54-44	9340-9348	software	_
54-45	9349-9351	to	_
54-46	9352-9360	identify	_
54-47	9361-9366	those	_
54-48	9367-9374	regions	_
54-49	9375-9379	that	_
54-50	9380-9388	survived	_
54-51	9389-9392	the	_
54-52	9393-9403	individual	_
54-53	9404-9415	comparisons	_
54-54	9416-9417	(	_
54-55	9418-9422	i.e.	_
54-56	9423-9424	,	_
54-57	9425-9438	schizophrenia	_
54-58	9439-9442	vs.	_
54-59	9443-9445	HC	_
54-60	9446-9447	;	_
54-61	9448-9461	schizophrenia	_
54-62	9462-9465	vs.	_
54-63	9466-9470	PTSD	_
54-64	9471-9472	;	_
54-65	9473-9486	schizophrenia	_
54-66	9487-9490	vs.	_
54-67	9491-9494	MDD	_
54-68	9495-9496	)	_
54-69	9497-9498	.	_

Text=Here the use of inclusive masking enabled a simple form of conjunction analysis that allowed us to identify alterations specific to the schizophrenia group.
55-1	9499-9503	Here	_
55-2	9504-9507	the	_
55-3	9508-9511	use	_
55-4	9512-9514	of	_
55-5	9515-9524	inclusive	_
55-6	9525-9532	masking	_
55-7	9533-9540	enabled	_
55-8	9541-9542	a	_
55-9	9543-9549	simple	_
55-10	9550-9554	form	_
55-11	9555-9557	of	_
55-12	9558-9569	conjunction	_
55-13	9570-9578	analysis	_
55-14	9579-9583	that	_
55-15	9584-9591	allowed	_
55-16	9592-9594	us	_
55-17	9595-9597	to	_
55-18	9598-9606	identify	_
55-19	9607-9618	alterations	_
55-20	9619-9627	specific	_
55-21	9628-9630	to	_
55-22	9631-9634	the	_
55-23	9635-9648	schizophrenia	_
55-24	9649-9654	group	_
55-25	9655-9656	.	_

Text=Alterations common to the three diagnostic groups were identified by comparing schizophrenia, PTSD, and MDD patients against HC (e.g., schizophrenia, PTSD and MDD vs. HC) and then using the inclusive masking option (at p <0.05 uncorrected) in SPM12 software to identify those regions that survived the diagnosis-specific comparisons (i.e., schizophrenia vs. HC; PTSD vs. HC; and MDD vs. HC).
56-1	9657-9668	Alterations	_
56-2	9669-9675	common	_
56-3	9676-9678	to	_
56-4	9679-9682	the	_
56-5	9683-9688	three	_
56-6	9689-9699	diagnostic	_
56-7	9700-9706	groups	_
56-8	9707-9711	were	_
56-9	9712-9722	identified	_
56-10	9723-9725	by	_
56-11	9726-9735	comparing	_
56-12	9736-9749	schizophrenia	_
56-13	9750-9751	,	_
56-14	9752-9756	PTSD	_
56-15	9757-9758	,	_
56-16	9759-9762	and	_
56-17	9763-9766	MDD	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
56-18	9767-9775	patients	_
56-19	9776-9783	against	_
56-20	9784-9786	HC	_
56-21	9787-9788	(	_
56-22	9789-9793	e.g.	_
56-23	9794-9795	,	_
56-24	9796-9809	schizophrenia	_
56-25	9810-9811	,	_
56-26	9812-9816	PTSD	_
56-27	9817-9820	and	_
56-28	9821-9824	MDD	_
56-29	9825-9828	vs.	_
56-30	9829-9831	HC	_
56-31	9832-9833	)	_
56-32	9834-9837	and	_
56-33	9838-9842	then	_
56-34	9843-9848	using	_
56-35	9849-9852	the	_
56-36	9853-9862	inclusive	_
56-37	9863-9870	masking	_
56-38	9871-9877	option	_
56-39	9878-9879	(	_
56-40	9880-9882	at	_
56-41	9883-9884	p	_
56-42	9885-9886	<	_
56-43	9887-9891	0.05	_
56-44	9892-9903	uncorrected	_
56-45	9904-9905	)	_
56-46	9906-9908	in	_
56-47	9909-9914	SPM12	_
56-48	9915-9923	software	_
56-49	9924-9926	to	_
56-50	9927-9935	identify	_
56-51	9936-9941	those	_
56-52	9942-9949	regions	_
56-53	9950-9954	that	_
56-54	9955-9963	survived	_
56-55	9964-9967	the	_
56-56	9968-9986	diagnosis-specific	_
56-57	9987-9998	comparisons	_
56-58	9999-10000	(	_
56-59	10001-10005	i.e.	_
56-60	10006-10007	,	_
56-61	10008-10021	schizophrenia	_
56-62	10022-10025	vs.	_
56-63	10026-10028	HC	_
56-64	10029-10030	;	_
56-65	10031-10035	PTSD	_
56-66	10036-10039	vs.	_
56-67	10040-10042	HC	_
56-68	10043-10044	;	_
56-69	10045-10048	and	_
56-70	10049-10052	MDD	_
56-71	10053-10056	vs.	_
56-72	10057-10059	HC	_
56-73	10060-10061	)	_
56-74	10062-10063	.	_

Text=Here the use of inclusive masking enabled us to detect alterations in schizophrenia group that reflect a trans-diagnostic feature of psychiatric illness.
57-1	10064-10068	Here	_
57-2	10069-10072	the	_
57-3	10073-10076	use	_
57-4	10077-10079	of	_
57-5	10080-10089	inclusive	_
57-6	10090-10097	masking	_
57-7	10098-10105	enabled	_
57-8	10106-10108	us	_
57-9	10109-10111	to	_
57-10	10112-10118	detect	_
57-11	10119-10130	alterations	_
57-12	10131-10133	in	_
57-13	10134-10147	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
57-14	10148-10153	group	_
57-15	10154-10158	that	_
57-16	10159-10166	reflect	_
57-17	10167-10168	a	_
57-18	10169-10185	trans-diagnostic	_
57-19	10186-10193	feature	_
57-20	10194-10196	of	_
57-21	10197-10208	psychiatric	_
57-22	10209-10216	illness	_
57-23	10217-10218	.	_

Text=Statistical inferences were made at p <0.05 after family-wise error (FWE) correction with a minimum extent threshold of 5 voxels.
58-1	10219-10230	Statistical	_
58-2	10231-10241	inferences	_
58-3	10242-10246	were	_
58-4	10247-10251	made	_
58-5	10252-10254	at	_
58-6	10255-10256	p	_
58-7	10257-10258	<	_
58-8	10259-10263	0.05	_
58-9	10264-10269	after	_
58-10	10270-10281	family-wise	_
58-11	10282-10287	error	_
58-12	10288-10289	(	_
58-13	10290-10293	FWE	_
58-14	10294-10295	)	_
58-15	10296-10306	correction	_
58-16	10307-10311	with	_
58-17	10312-10313	a	_
58-18	10314-10321	minimum	_
58-19	10322-10328	extent	_
58-20	10329-10338	threshold	_
58-21	10339-10341	of	_
58-22	10342-10343	5	_
58-23	10344-10350	voxels	_
58-24	10351-10352	.	_

Text=Post hoc correlation analysis in schizophrenia To further elucidate the above alterations, a series of exploratory post hoc correlation analyses were performed with clinical scores in patients with schizophrenia using IBM SPSS version 21.0 (IBM Corp, Armonk, NY, USA).
59-1	10353-10357	Post	_
59-2	10358-10361	hoc	_
59-3	10362-10373	correlation	_
59-4	10374-10382	analysis	_
59-5	10383-10385	in	_
59-6	10386-10399	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
59-7	10400-10402	To	_
59-8	10403-10410	further	_
59-9	10411-10420	elucidate	_
59-10	10421-10424	the	_
59-11	10425-10430	above	_
59-12	10431-10442	alterations	_
59-13	10443-10444	,	_
59-14	10445-10446	a	_
59-15	10447-10453	series	_
59-16	10454-10456	of	_
59-17	10457-10468	exploratory	_
59-18	10469-10473	post	_
59-19	10474-10477	hoc	_
59-20	10478-10489	correlation	_
59-21	10490-10498	analyses	_
59-22	10499-10503	were	_
59-23	10504-10513	performed	_
59-24	10514-10518	with	_
59-25	10519-10527	clinical	_
59-26	10528-10534	scores	_
59-27	10535-10537	in	_
59-28	10538-10546	patients	_
59-29	10547-10551	with	_
59-30	10552-10565	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
59-31	10566-10571	using	_
59-32	10572-10575	IBM	_
59-33	10576-10580	SPSS	_
59-34	10581-10588	version	_
59-35	10589-10593	21.0	_
59-36	10594-10595	(	_
59-37	10596-10599	IBM	_
59-38	10600-10604	Corp	_
59-39	10605-10606	,	_
59-40	10607-10613	Armonk	_
59-41	10614-10615	,	_
59-42	10616-10618	NY	_
59-43	10619-10620	,	_
59-44	10621-10624	USA	_
59-45	10625-10626	)	_
59-46	10627-10628	.	_

Text=This identified three significant correlations with clinical scores.
60-1	10629-10633	This	_
60-2	10634-10644	identified	_
60-3	10645-10650	three	_
60-4	10651-10662	significant	_
60-5	10663-10675	correlations	_
60-6	10676-10680	with	_
60-7	10681-10689	clinical	_
60-8	10690-10696	scores	_
60-9	10697-10698	.	_

Text=First, the trans-diagnostic EC increase between the left MDN and the right medial superior frontal gyrus was negatively correlated with the PANSS negative score (Pearson correlation = −0.328; two-tailed p-value: 0.020).
61-1	10699-10704	First	_
61-2	10705-10706	,	_
61-3	10707-10710	the	_
61-4	10711-10727	trans-diagnostic	_
61-5	10728-10730	EC	_
61-6	10731-10739	increase	_
61-7	10740-10747	between	_
61-8	10748-10751	the	_
61-9	10752-10756	left	_
61-10	10757-10760	MDN	_
61-11	10761-10764	and	_
61-12	10765-10768	the	_
61-13	10769-10774	right	_
61-14	10775-10781	medial	_
61-15	10782-10790	superior	_
61-16	10791-10798	frontal	_
61-17	10799-10804	gyrus	_
61-18	10805-10808	was	_
61-19	10809-10819	negatively	_
61-20	10820-10830	correlated	_
61-21	10831-10835	with	_
61-22	10836-10839	the	_
61-23	10840-10845	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
61-24	10846-10854	negative	_
61-25	10855-10860	score	_
61-26	10861-10862	(	_
61-27	10863-10870	Pearson	_
61-28	10871-10882	correlation	_
61-29	10883-10884	=	_
61-30	10885-10891	−0.328	_
61-31	10892-10893	;	_
61-32	10894-10904	two-tailed	_
61-33	10905-10912	p-value	_
61-34	10913-10914	:	_
61-35	10915-10920	0.020	_
61-36	10921-10922	)	_
61-37	10923-10924	.	_

Text=Second, the trans-diagnostic EC increase between the left MDN and the right putamen was positively correlated with the Global Assessment of Functioning scores (Pearson correlation = 0.389; two-tailed p-value: 0.005).
62-1	10925-10931	Second	_
62-2	10932-10933	,	_
62-3	10934-10937	the	_
62-4	10938-10954	trans-diagnostic	_
62-5	10955-10957	EC	_
62-6	10958-10966	increase	_
62-7	10967-10974	between	_
62-8	10975-10978	the	_
62-9	10979-10983	left	_
62-10	10984-10987	MDN	_
62-11	10988-10991	and	_
62-12	10992-10995	the	_
62-13	10996-11001	right	_
62-14	11002-11009	putamen	_
62-15	11010-11013	was	_
62-16	11014-11024	positively	_
62-17	11025-11035	correlated	_
62-18	11036-11040	with	_
62-19	11041-11044	the	_
62-20	11045-11051	Global	_
62-21	11052-11062	Assessment	_
62-22	11063-11065	of	_
62-23	11066-11077	Functioning	_
62-24	11078-11084	scores	_
62-25	11085-11086	(	_
62-26	11087-11094	Pearson	_
62-27	11095-11106	correlation	_
62-28	11107-11108	=	_
62-29	11109-11114	0.389	_
62-30	11115-11116	;	_
62-31	11117-11127	two-tailed	_
62-32	11128-11135	p-value	_
62-33	11136-11137	:	_
62-34	11138-11143	0.005	_
62-35	11144-11145	)	_
62-36	11146-11147	.	_

Text=Third, the trans-diagnostic EC increase between the right MDN and the right medial superior frontal gyrus was negatively associated with the PANSS general psychopathology score (Pearson correlation = −0.323; two-tailed p-value: 0.022).
63-1	11148-11153	Third	_
63-2	11154-11155	,	_
63-3	11156-11159	the	_
63-4	11160-11176	trans-diagnostic	_
63-5	11177-11179	EC	_
63-6	11180-11188	increase	_
63-7	11189-11196	between	_
63-8	11197-11200	the	_
63-9	11201-11206	right	_
63-10	11207-11210	MDN	_
63-11	11211-11214	and	_
63-12	11215-11218	the	_
63-13	11219-11224	right	_
63-14	11225-11231	medial	_
63-15	11232-11240	superior	_
63-16	11241-11248	frontal	_
63-17	11249-11254	gyrus	_
63-18	11255-11258	was	_
63-19	11259-11269	negatively	_
63-20	11270-11280	associated	_
63-21	11281-11285	with	_
63-22	11286-11289	the	_
63-23	11290-11295	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
63-24	11296-11303	general	_
63-25	11304-11319	psychopathology	_
63-26	11320-11325	score	_
63-27	11326-11327	(	_
63-28	11328-11335	Pearson	_
63-29	11336-11347	correlation	_
63-30	11348-11349	=	_
63-31	11350-11356	−0.323	_
63-32	11357-11358	;	_
63-33	11359-11369	two-tailed	_
63-34	11370-11377	p-value	_
63-35	11378-11379	:	_
63-36	11380-11385	0.022	_
63-37	11386-11387	)	_
63-38	11388-11389	.	_

